

(62)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 24, 2006.

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

INFORMATION DISCLOSURE
STATEMENT
Examining Group 1645
Patent Application
Docket No. C&R-100
Serial No. 10/531,751

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (not yet assigned)
Art Unit : 1645
Applicants : Richard Joseph Fagan, Christopher Benjamin Phelps, Tania Maria Rodrigues,
Christine Power, Jadwiga Bienkowska
Serial No. : 10/531,751
Filed : April 18, 2005
Conf. No. : 6010
For : Alpha Macroglobulin Protein Family Members

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:


The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 U.S.C. §371. The applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notification of Acceptance of the Application under 35 U.S.C. §371 (Form PCT/DO/EO/903). The Notification does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience.

The applicants have also listed on form PTO/SB/08 numerous references which have not been cited in the International Search Report (citations R5-R27). Copies of these references are also enclosed with this IDS.

In accordance with 37 C.F.R. §1.56, the applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,



Glenn P. Ladwig
Patent Attorney
Registration No. 46,853
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
P.O. Box 142950
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (4 pages); copies of cited references



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, you are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/531,751
				Filing Date	April 18, 2005
				First Named Inventor	Richard Joseph Fagan
				Art Unit	1645
				Examiner Name	
Sheet	1	of	4	Attorney Docket Number	C&R-100

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
F1		WO 91/03557 A1	03-21-1991	Novo Nordisk A/S	All
F					
F					
F					
F					
F					

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	2	of	4	Application Number	10/531,751
				Filing Date	April 18, 2005
				First Named Inventor	Richard Joseph Fagan
				Group Art Unit	1645
				Examiner Name	
				Attorney Docket Number	C&R-100

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	R1	DEVRIENDT, K. et al. "Primary structure of pregnancy zone protein molecular cloning of a full-length PZP complementary DNA clone by the polymerase chain reaction" <i>Biochimica et Biophysica Acta</i> , 1991, 1088(1):95-103.			
	R2	KAN, C-C. et al. "Nucleotide sequence of cDNA encoding human alpha2-macroglobulin and assignment of the chromosomal locus" <i>Proc. Natl. Acad. Sci. USA</i> , 1985, 82(8):2282-2286.			
	R3	DATABASE EMBL ONLINE, February 13, 2002 "Novel human diagnostic protein #5706" retrieved from EBI Database accession no. ABG05715 & WO 01/75067.			
	R4	DATABASE EMBL ONLINE, February 13, 2002 "DNA encoding novel human diagnostic protein #5706" retrieved from EBI Database accession no. AAS69902 & WO 01/75067.			
	R5	ASAMI, T. et al. "Study on proteinase-inhibiting capacity of plasma α_2 -macroglobulin in idiopathic nephritic syndrome"			
	R6	BHATIA, M. et al. "Complement factor C5a exerts an anti-inflammatory effect in acute pancreatitis and associated lung injury" <i>Am. J. Physiol. Gastrointest. Liver Physiol.</i> , 2001, 280:G974-G978.			
	R7	CISŁO, M. et al. "Allelic distribution of complement components BF, C4A, C4B, and C3 in <i>Psoriasis vulgaris</i> " <i>Immunology Letters</i> , 2002, 80:145-149.			
	R8	EGGERTSEN, G. et al. "Sequence of rat α_1 -macroglobulin, a broad-range proteinase inhibitor from the α -macroglobulin-complement family" <i>Mol. Biol. Med.</i> , 1991, 8:287-302.			
	R9	FRITZINGER, D. et al. "Primary structure of cobra complement component C3" <i>J. Immunology</i> , 1992, 149:3554-3562.			
	R10	GENNARO, R. et al. "C5a fragment of bovine complement" <i>Eur. J. Biochem.</i> , 1986, 155:77-86.			
	R11	GHEBREMEDHIN, E. et al. "Genetic association of argyrophilic grain disease with polymorphisms in alpha-2 macroglobulin and low-density lipoprotein receptor-related protein genes" <i>Neuropath. App. Neurobiol.</i> , 2002, 28:308-313.			
	R12	HONG, T. et al. "A study on the serum pregnancy zone protein levels in pregnant women and patients with gynecological tumors" <i>Chinese Med. J.</i> , 1994, 107:910-914.			
	R13	KÖHL, J. "Anaphylatoxins and infectious and non-infectious inflammatory diseases" <i>Mol. Immunology</i> , 2001, 38:175-187.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	3	of	4	Application Number	10/531,751
				Filing Date	April 18, 2005
				First Named Inventor	Richard Joseph Fagan
				Group Art Unit	1645
				Examiner Name	
				Attorney Docket Number	C&R-100

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R14	LIN, M. et al. "Cell surface antigen CD109 is a novel member of the α_2 macroglobulin/C3, C4, C5 family of thioester-containing proteins" <i>Blood</i> , 2002, 99:1683-1691.		
	R15	NAGASE, H. et al. "Evidence for a thiol ester in duck ovostatin (ovomacroglobulin)" <i>J. Biol. Chem.</i> , 1986, 261:1421-1426.		
	R16	NICOLETTI, G. et al. "No evidence of association between the alpha-2 macroglobulin gene and Parkinson's disease in a case-control sample" <i>Neurosci. Letters</i> , 2002, 328:65-67.		
	R17	NIELSON, K. et al. "Identification of residues in α -macroglobulins important for binding to the α_2 -macroglobulin receptor/low density lipoprotein receptor-related protein" <i>J. Biol. Chem.</i> , 1996, 271:12909-12912.		
	R18	O'BARR, S. and COOPER, N. "The C5a complement activation peptide increases IL-1 β and IL-6 release from amyloid- β primed human monocytes: implications for Alzheimer's disease"		
	R19	OGATA, R. et al. "Sequence of the gene for murine complement component C4" <i>J. Biol. Chem.</i> , 1989, 264:16565-16572.		
	R20	PETERSEN, C. " α_2 -macroglobulin and pregnancy zone protein" <i>Danish Med. Bull.</i> , 1993, 40:409-446.		
	R21	QAZI, U. et al. "On the structural changes of native human α_2 -macroglobulin upon proteinase entrapment" <i>J. Biol. Chem.</i> , 1998, 273:8987-8993.		
	R22	RAMOS, A. et al. " <i>Trypanosoma cruzi</i> : cruzipain and membrane-bound cysteine proteinase isoform(s) interacts with human α_2 -macroglobulin and pregnancy zone protein" <i>Exper. Parasitology</i> , 2002, 100:121-130.		
	R23	SANDOVAL, A. et al. "Distal recognition site for classical pathway convertase located in the C345C/Netrin module of complement component C5" <i>J. Immunology</i> , 2000, 165:1066-1073.		
	R24	SHERNAN, S. and COLLARD, C. "Role of the complement system in ischaemic heart disease" <i>BioDrugs</i> , 2001, 15:595-607.		
	R25	SOTTRUP-JENSEN, L. " α -macroglobulins: structure, shape, and mechanism of proteinase complex formation" <i>J. Biol. Chem.</i> , 1989, 264:11539-11542.		
	R26	TANG, G. et al. "Alpha-2 macroglobulin I1000V polymorphism in Chinese sporadic Alzheimer's disease and Parkinson's disease" <i>Neurosci. Letters</i> , 2002, 328:195-197.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	4	of	4	Application Number	10/531,751
				Filing Date	April 18, 2005
				First Named Inventor	Richard Joseph Fagan
				Group Art Unit	1645
				Examiner Name	
				Attorney Docket Number	C&R-100

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R27	ZAPPIA, M. et al. "Genetic association of α_2 -macroglobulin polymorphisms with AD in southern Italy" <i>Neurology</i> , 2002, 59:756-758.		
	R			
	R			
	R			
	R			
	R			
	R			
	R			
	R			
	R			
	R			
	R			
	R			
	R			
	R			
	R			
	R			
	R			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.